Thinking About Peptides? Here Are 5 Things to Know.

Peptides are everywhere right now, moving quickly from clinical settings into mainstream conversation. That visibility has brought both increased interest and increased confusion, making it harder to separate established science from emerging or unsupported claims.

At their core, peptides are not new. They have been used in clinical medicine for decades. Empower Pharmacy currently compounds a range of peptide therapies for provider use, grounded in established pharmacy standards and prepared within regulated pharmacy environment. What is changing is how broadly they are being studied and how often they are discussed outside traditional regulatory and clinical frameworks (Rossino et al., 2023).

As Dr. Mark L. Gordon notes in Peptides for Health:

“They are being used in neuroregeneration, metabolic repair, immune modulation, recovery, and longevity—yet most clinicians…were never taught how they work or how to apply them responsibly.”

At the same time, many of these areas remain investigational, with varying levels of clinical evidence and no established consensus for routine use. That gap between growing interest and foundational understanding is where both opportunity and risk sit.

For patients and providers alike, understanding the difference between established use and emerging applications is essential.

Below are five key concepts to help ground the conversation around peptides and their role in medicine.

1. Peptides Are Natural Messengers in the Body

Peptides are short chains of amino acids that act as signaling molecules, helping regulate functions like metabolism, immune response, and tissue repair (Rossino et al., 2023).

What makes them relevant in medicine is how they interact with the body’s existing biology. By binding to specific receptors, peptides are understood to affect targeted biological pathways. The clinical impact of these interactions depends on the individual peptide and the strength of available evidence.

This is not a new frontier. It reflects mechanisms medicine has relied on for decades. Many well-established therapies are peptide-based, including insulin, oxytocin, calcitonin, and GLP-1 receptor agonists (Rossino, 2026).

2. Peptide Therapeutics Have a Long History

Peptides have been used in clinical medicine for more than a century. In 1921, insulin became the first therapeutic peptide, transforming the treatment of diabetes and establishing a foundation for peptide-based therapies (Rossino, 2026).

Advances in recombinant DNA technology later enabled the development of additional peptide therapies, including GnRH analogs, somatostatin analogs, and calcitonin derivatives (Wang, 2022).

What has changed in recent years is the pace and scope of research. Peptide development has expanded into areas such as metabolic disease, oncology, autoimmune conditions, and reproductive medicine.

More recently, attention has turned toward what some providers are calling “functional peptides.” This includes thymosin peptides, mitochondrial-derived peptides like MOTS-c, growth hormone secretagogues, and angiogenic peptides. Many of these remain investigational, highlighting the distinction between established therapies and emerging areas of study (Wang, 2022; Bellman-Sickert, et al., 2018; Singh, et al., 2022).

3. Peptides Are a Growing Segment of the Pharmaceutical Market

Peptide therapeutics are no longer a niche category. Today, they represent an estimated 5–10% of the global pharmaceutical market, with continued growth driven by ongoing research and clinical interest (Grandview Research, 2023).

Because peptides can target specific biological pathways and receptors, they are being studied as a way to better understand and potentially influence processes such as hormone signaling and immune response.

This has contributed to the development and approval of more than 100 peptide-based drugs globally, alongside a growing research pipeline (Musiami, 2024).

4. Regulatory Frameworks Are Central to Peptide Use

As interest in peptides has expanded, so has the importance of regulatory oversight. Peptides may be available as FDA-approved drugs or, in certain cases, as compounded preparations under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDA, 2021).

In response to the growing use of peptides, in 2023 FDA identified potential significant safety risks of certain bulk substances used in compounding. These substances are evaluated based on safety and available evidence, with certain peptides categorized as ineligible for compounding due to potential risk (FDA, 2025).

Recent FDA communications and actions suggest a continued evolution in policy related to compounding and the use of certain bulk substances, including peptides. This includes ongoing evaluation of substances nominated for compounding, clarification of enforcement priorities, and increased emphasis on aligning compounding practices with statutory and evidentiary standards.

Collectively, these signals indicate that additional regulatory guidance or policy refinement may be forthcoming as the Agency continues to assess safety, quality, and appropriate use within this category (FDA, 2024). For both providers and patients, this regulatory landscape is central to understanding how peptide therapies are evaluated, accessed, and used.

5. Clinical Use Requires Attention to Evidence, Quality, and Oversight

Peptides are being studied and, in some cases, used in clinical practice across areas such as metabolic and endocrine conditions. Other potential applications, including those often discussed in regenerative contexts, remain investigational and continue to be evaluated.

At the same time, demand has expanded beyond traditional clinical and regulatory channels (Hahamyan et al., 2025). Some peptides are marketed through “research use” suppliers and other unregulated sources, often without consistent quality standards or clinical oversight.

This gap between growing demand and uneven evidence makes a clinically grounded approach essential. The use of peptide therapies should prioritize evidence-based decision-making where available, careful evaluation of risks and benefits, appropriate regulatory alignment, and ongoing attention to emerging safety data (Petrou et al., 2025).

The Bottom Line

Peptides occupy an important and evolving role in modern medicine.

Some therapies are well established, supported by decades of clinical use and robust evidence. Others remain investigational, with ongoing scientific study and regulatory evaluation.

Understanding the distinction between these categories is essential to informed clinical decision-making.

As interest continues to grow, the path forward requires balancing scientific progress with evidence, safety, and appropriate oversight.